From a therapeutic point of view, because PDL1 expression in could indicate an adaptive mechanism of immune escape [65], the blockade of PDL1 should protect activated T-cells or reactivate inhibited T-cells and increase the anti-tumor immune response, thus improving the therapeutic response, notably when associated with immunogenic anticancer chemotherapy such as doxorubicin [66, 67]. Here, CD274 is linked to neoplasm.